metaPreg - Midazolam during pregnancy

Midazolam updated on 02-10-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.26 [1.17, 1.35]	-	1 study	157,637	8,609	not evaluable	ROB	1.83 [1.62; .]
Congenital heart defects	1.34 [1.22, 1.47]	-	1 study	84,054	8,609	not evaluable	ROB	2.01 [1.74; .]
Major congenital malformations	1.26 [1.17, 1.35]	-	1 study	157,637	8,609	not evaluable	ROB	1.83 [1.62; .]
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	1.35 [1.14, 1.60]	-	1 study	266,124	1,269	not evaluable	ROB	2.04 [1.54; .]
Small for gestational age (weight)	1.32 [1.12, 1.56]	-	1 study	273,301	1,318	not evaluable	ROB	1.97 [1.48; .]
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Late intrauterine deaths (> 22 weeks) / Stillbirths	2.70 [1.99, 3.67]	-	1 study	36,541	1,317	not evaluable	ROB	4.84 [3.38; .]